Mitral Stenosis: Severity Assessment

This page is a technique-focused companion to the Mitral Stenosis overview — it goes deeper into how each severity measurement is actually made, where each one breaks, and how to reconcile them when they disagree. If you need etiology, auscultation, or the Wilkins score’s role in treatment planning first, start there.

Full echocardiographic evaluation of mitral stenosis (MS) severity rests on a triad: (1) mitral valve area (MVA), (2) the mean diastolic transmitral pressure gradient, and (3) the downstream hemodynamic consequences — left atrial size and pulmonary pressures. None of the three is reliable in isolation, and the sections below work through each measurement method, its derivation, and the specific situations in which it misleads.

Mean Transmitral Pressure Gradient

The mean gradient is obtained by tracing the continuous-wave (CW) Doppler diastolic mitral inflow spectrum from an apical four- or two-chamber view and applying the simplified Bernoulli equation to the instantaneous velocities, then averaging:

ΔP (mean) = average of 4v² across the diastolic filling period

Why mean, not peak: the peak gradient is driven by the peak mitral velocity, which is itself influenced by LA compliance, LV diastolic function, and loading conditions — it is not a reliable severity marker. The mean gradient is the more clinically relevant number, though it is still flow- and rate-dependent rather than a pure measure of orifice size.

Technical pitfalls:

• Confusing the MS jet with a concurrent aortic regurgitation (AR) jet. Both produce diastolic Doppler signals in similar windows. The AR velocity curve starts earlier in diastole and reaches a higher velocity than the MS jet — look at onset timing and peak velocity to separate them.
• Associated mitral regurgitation (MR) overestimates severity. MR increases transmitral volume flow, which raises the mean gradient independent of any change in valve area.
• Heart rate and flow dependence. ΔP is proportional to flow², so exercise, fever, anemia, and pregnancy (which can raise cardiac output up to 1.7-fold, theoretically translating to a 1.7–2.9-fold rise in gradient) can all markedly increase the measured gradient without the valve itself changing. Always report the heart rate at which the gradient was measured.
• Atrial fibrillation. Average the gradient over five cardiac cycles, choosing beats with an instantaneous rate close to 60–90 bpm when possible; a very rapid rate limits transmitral flow and biases the average low.
• Alignment. The intercept angle between the ultrasound beam and the transmitral jet should be as close to 0° as possible (current handbook guidance: within 20°) to avoid underestimating velocity.
• Mitral annular calcification (MAC) with a prominent A-wave. In sinus rhythm, a large late-diastolic A-wave from MAC-related diastolic dysfunction can push the calculated mean gradient into the “severe” range despite only mild-to-moderate true orifice narrowing — a recognized cause of pseudo-severe MS. Some labs measure the gradient omitting the A-wave in this scenario; borderline cases merit multidisciplinary discussion incorporating 2D and color-Doppler impressions, not the gradient number alone.

Mitral Valve Area by Planimetry

Planimetry measures the anatomic orifice area directly, rather than inferring a functional area from flow or pressure data — and unlike the Doppler-derived methods below, it is relatively load-independent.

2D technique:

1. Obtain a parasternal short-axis view at the level of the mitral leaflet tips.
2. Scan slowly from the LV apex toward the base (or from the mid-papillary-muscle level up toward the mitral annulus), since the mitral inflow region is funnel-shaped and the narrowest cross-section is specifically at the leaflet tips.
3. Select the mid-diastolic frame with maximal leaflet separation.
4. Use a low overall gain setting and trace the inner edge of the black–white interface — high gain underestimates the orifice; too-low gain or an oblique imaging plane overestimates it.
5. Average several cardiac cycles — at least three in sinus rhythm, at least five in atrial fibrillation.

Why 2D planimetry can fail: it depends entirely on finding the true leaflet-tip plane, and the tips are frequently located eccentrically, outside a single tomographic short-axis plane. A plane that is too close to the annulus, or that transects the mid-leaflet rather than the tips, overestimates MVA; an oblique plane that excludes one commissure does too. Other limitations include a poor acoustic window, severe leaflet-tip calcification with shadowing/reverberation artifact, and a deformed, irregular orifice after commissurotomy or balloon valvuloplasty.

3D planimetry is now considered the echocardiographic gold standard for MVA. By acquiring a full-volume data set (TTE or TEE) and reslicing in multiple planes, 3D guidance lets you confirm that the measurement plane truly sits at the leaflet tips rather than assuming a single fixed short-axis cut is correct — directly addressing 2D planimetry’s main failure mode. Methods include:

• Multiplanar reformatting (MPR) of a 3D data set to localize the true leaflet tips before tracing — generally considered the most accurate approach.
• Direct on-image 3D planimetry, available on newer ultrasound systems.
• Grid-based estimation on older systems, where each grid rectangle corresponds to a fixed area (e.g., 0.25 cm² for a 5×5 mm grid) and the orifice is estimated by counting covered squares.
• Biplane/x-plane imaging, which lets you adjust a second simultaneous plane to confirm the measurement plane transects the leaflet edges correctly.

3D imaging is also the best way to characterize the degree and asymmetry of commissural fusion, both at baseline and after intervention.

Pressure Half-Time

Pressure half-time (PHT) is the simplest and most widely used Doppler method for estimating functional MVA, but it is a surrogate — it estimates how fast the LA–LV pressure gradient decays, not the orifice itself, so anything else that changes that decay rate independent of the valve will bias it.

Physiologic basis: the empirical formula

MVA (cm²) = 220 / PHT (ms)

was derived by relating invasively measured LA–LV half-times to Gorlin-equation valve areas, finding that a half-time of ~220 ms corresponded to a valve area of ~1 cm². It was developed specifically for rheumatic MS and should not be applied to, for example, senile calcific MS.

How to measure it: PHT is the time interval from the peak early-diastolic transmitral velocity (Vmax) to the point where velocity has fallen to Vmax/√2 (equivalent to the pressure falling to half its peak value, since pressure gradient scales with velocity squared). Trace it from the mid-diastolic, linear portion of the deceleration slope — not the initial steep early-diastolic segent, which can be disproportionately fast and is specifically excluded from the measurement. When the deceleration curve shows two distinct slopes (common when MS coexists with MR), use the slower, later slope. CW Doppler is now generally preferred over pulsed-wave for this measurement, though PW (including high-PRF) can show a cleaner early slope in some cases.

A closely related alternative — mitral deceleration time (DT): DT is the time from peak E-wave velocity to zero velocity (end of antegrade flow). Because PHT ≈ 0.29 × DT, MVA can also be estimated as:

MVA (cm²) = 759 / DT (ms)

DT is useful when a clean PHT trace isn’t obtainable.

When PHT overestimates or underestimates MVA — the single most important limitation to internalize:

Situation	Effect on PHT	Effect on calculated MVA
Significant aortic regurgitation	Shortened (LV pressure rises faster from AR inflow)	Overestimated
Large atrial septal defect (Lutembacher physiology)	Shortened (LA decompressed via left-to-right shunt)	Overestimated
Reduced LV compliance / diastolic dysfunction (common in older patients)	Shortened	Overestimated
Severe AR impairing mitral leaflet opening	Lengthened (functional MS superimposed on anatomic MS)	Underestimated
Abnormal LV relaxation (as opposed to reduced compliance)	Lengthened	Underestimated
First 24–72 hours after balloon commissurotomy	Unpredictable — LA/LV compliance actively re-equilibrating	Unreliable; avoid using PHT in this window

The underlying assumption that LA and LV compliance don’t materially affect the rate of pressure decline is reasonable in a hemodynamically stable patient, but is specifically not valid immediately post-commissurotomy, when LA pressure is falling and LV filling rising at the same time the chambers’ compliances are both changing. Wait until the 24–72 hour re-equilibration period has passed before trusting PHT again.

In mitral annular calcification, the 220/PHT formula lacks validation entirely and should not be used.

Continuity Equation and Doppler Volumetric Method

The continuity equation applies the principle that stroke volume across one orifice (the LV outflow tract, in the absence of significant aortic or mitral regurgitation) equals stroke volume across another orifice in the same closed circuit (the stenotic mitral valve):

MVA = (LVOT area × LVOT VTI) / MV VTI

LVOT area is calculated from the parasternal long-axis LVOT diameter assuming a circular cross-section; LVOT and transmitral VTIs are obtained by pulsed-wave and CW Doppler respectively.

Limitations: this method is time-consuming and more prone to cumulative measurement error than planimetry or PHT. Beyond significant coexisting MR or AR (which break the equal-stroke-volume assumption), the dominant error source is LVOT diameter — both mismeasurement and the LVOT’s frequent noncircularity. The method should generally be avoided in atrial fibrillation. It is most useful specifically when other methods disagree and a independent cross-check is needed.

PISA for Mitral Stenosis

The proximal isovelocity surface area (PISA) method is less commonly used for MS than for regurgitant lesions, but it has one specific advantage: it remains valid even when significant concomitant MR is present, because the increased diastolic flow from MR affects the flow at both the isovelocity hemisphere and the leaflet-tip orifice equally, so the ratio-based calculation still holds.

Why it’s technically demanding: PISA assumes blood flow forms a hemispherical isovelocity shell as it accelerates toward the orifice. For a planar, 180°-opening orifice, this is straightforward. But the stenotic mitral orifice is funnel-shaped, meeting at an angle less than 180° — so the isovelocity shells are only partial hemispheres, and the basic formula must be corrected for the actual leaflet opening angle (θ):

MVA = 2πr² × (V_alias / Vmax) × (θ / 180°)

where r is the PISA radius (cm), V_alias is the color-Doppler aliasing velocity at the shell boundary (cm/s), Vmax is the maximum transmitral CW Doppler velocity (cm/s), and θ is the angle between the two mitral leaflets in diastole, measured from the 2D image.

Practical acquisition: shift the color-Doppler baseline in the direction of flow to bring the aliasing velocity into a measurable range (typically 25–30 cm/s), and capture the frame in mid-diastole where the flow-convergence region, jet expansion into the LV, and the isovelocity surface are all well seen. Measuring the leaflet opening angle accurately is the step most prone to error, which is why PISA remains a secondary rather than first-line method for MS despite its MR-tolerance advantage.

3D and Advanced Imaging — Summary

• 3D-guided planimetry (TTE or TEE) is the current reference standard for MVA, as detailed above — it directly visualizes the orifice rather than inferring it, and it is the most reliable method for re-assessing valve area after balloon commissurotomy, when the irregular post-procedure orifice is especially hard to planimeter accurately in 2D.
• Multiplane reconstruction (MPR) from a 3D TEE data set specifically allows localization of the true leaflet tips, which 2D short-axis imaging cannot guarantee.
• See Three-Dimensional Echocardiography and Transesophageal Echocardiography for the acquisition techniques themselves.

Guideline-Based Severity Grading

Current staging (2020 ACC/AHA Table 16; the 2025 ESC/EACTS guideline uses an equivalent MVA threshold):

Stage	Definition	Valve Anatomy	Hemodynamics	Consequences	Symptoms
A	At risk of MS	Mild valve doming in diastole	Normal transmitral flow velocity	None	None
B	Progressive MS	Rheumatic changes, commissural fusion, diastolic doming	MVA >1.5 cm²; PHT under 150 ms	Mild–moderate LA enlargement; normal resting pulmonary pressure	None
C	Asymptomatic severe MS	As above	MVA ≤1.5 cm²; PHT ≥150 ms	Severe LA enlargement; PASP >50 mmHg	None
D	Symptomatic severe MS	As above	MVA ≤1.5 cm²; PHT ≥150 ms	Severe LA enlargement; PASP >50 mmHg	Decreased exercise tolerance; exertional dyspnea

The mean transmitral gradient (typically >5–10 mmHg in severe MS at a normal heart rate) is still routinely reported, but — because of its strong dependence on heart rate and flow — it is not part of the formal staging criteria in either current guideline.

Classic (descriptive) three-tier grading, still widely used in report templates and worth knowing because it predates and differs from the current staging:

Severity	MVA	Pressure half-time	Mean gradient
Mild	>1.5 cm²	under 150 ms	under 5 mmHg
Moderate	1.0–1.5 cm²	150–220 ms	5–10 mmHg
Severe	under 1.0 cm²	>220 ms	>10 mmHg

These two schemes are not interchangeable, and this is the single most common point of confusion when comparing a report to guideline language. The classic scheme descriptively grades stenosis across a continuum and reserves “severe” for an MVA under 1.0 cm². The current guideline staging instead identifies the MVA threshold (≤1.5 cm²) at which intervention timing starts to meaningfully change outcomes — a materially lower bar for “severe” than the classic scheme implies. When reporting for clinical decision-making, use the guideline threshold; the classic tiers remain useful for describing mild-to-moderate disease.

Low-Gradient Severe Mitral Stenosis

The 2025 ESC/EACTS guideline explicitly names low-gradient severe MS — an MVA under 1.5 cm² together with a mean gradient under 10 mmHg — as a distinct and challenging pattern to manage. These patients are typically older, with unfavorable valve anatomy (extensive calcification, reduced leaflet mobility), and the mismatch between a severe-range MVA and a disproportionately low gradient reflects reduced transmitral flow rather than milder disease. Management in this group requires the same individualized, Heart Team-based approach used for low-flow, low-gradient aortic stenosis: confirm the MVA measurement’s accuracy (ideally with 3D planimetry), look for a cause of reduced flow, and weigh exercise or dobutamine hemodynamics against resting numbers before committing to a severity label.

Degenerative MS and Mitral Annular Calcification

Calcific MS related to mitral annular calcification (MAC) is a distinct pathology from rheumatic MS, both anatomically and in how it should be assessed:

Feature	Rheumatic MS	Degenerative MS (MAC)
Calcification location	Leaflet tips/free edges first	Basal leaflet and annulus; free edges spared
Leaflet motion	Commissural fusion; leaflets move in tandem (“parallel”)	No commissural fusion; leaflets move independently (“antiparallel”), reduced amplitude
Chordal involvement	Thickening, shortening, fusion	Typically absent
Limiting orifice location	Leaflet tips	Base of the leaflets
Response to balloon commissurotomy	Good (relieves commissural fusion)	Not amenable — there is no commissural fusion to split

Why standard quantitation methods struggle here: planimetry at the leaflet-tip plane doesn’t capture the true limiting orifice, which in MAC sits more basally; severe calcification causes shadowing and blooming artifact that can obscure the orifice entirely; and none of the classic echocardiographic techniques (planimetry, PHT, PISA, continuity equation) are validated for degenerative MS. In practice, the mean transmitral gradient under stable loading conditions is the more dependable diagnostic tool in this group, and electrocardiogram-gated CT is often needed to characterize the extent of calcification, especially when an intervention is being planned. Degenerative MS is most often mild-to-moderate and only rarely reaches severe.

The progression rate of calcific MS is highly variable (reported anywhere from under 1.0 to up to 9 mmHg per year in mean gradient), and prognosis in this generally elderly, comorbid population is poor independent of the valve itself — which further complicates using echocardiographic severity alone to drive intervention timing.

MAC is by far the most common nonrheumatic mimic of MS, but it is not the only one: a left-sided carcinoid plaque in carcinoid heart disease can occasionally restrict mitral inflow in a similar way, usually in the setting of a right-to-left shunt or pulmonary metastases that let serotonin-rich blood reach the left heart. These nonrheumatic etiologies share MAC’s limitation — none of the standard quantitation methods above are validated for them — so recognizing the underlying pathology from leaflet and annular morphology, not just from the numbers, is essential.

Role of Exercise and Hemodynamic Stress Testing

Exercise testing has a Class I indication (2020 ACC/AHA; equivalent in the 2025 ESC/EACTS guideline) whenever there is a discrepancy between resting echocardiographic severity and the patient’s clinical symptoms — a common scenario, since MS symptom onset can be insidious and some patients unconsciously limit their activity long before recognizing exertional dyspnea.

What’s measured: the mean transmitral gradient (CW Doppler across the MV) and the systolic pulmonary artery pressure (from the tricuspid regurgitant jet), compared at rest and at peak stress.

Thresholds indicating hemodynamically significant MS on exercise echocardiography:

• Mean mitral gradient rising to >15 mmHg, or
• Systolic PAP rising to >60 mmHg

On dobutamine stress echocardiography specifically, the threshold for a severe mean gradient is slightly higher, at 18 mmHg (reported sensitivity ~90%, specificity ~87%), reflecting that DSE is a less physiologic stimulus than exercise.

Protocol notes: treadmill exercise (commonly the modified Bruce protocol in North America) allows post-exercise imaging only; semi-supine bicycle/ergocycle testing (more common in Europe) permits image acquisition at each stage of exercise itself, which is an advantage for capturing a true peak-stress value. A symptom-limited test aiming for at least 85% of the age-predicted maximum heart rate is recommended, with patients continuing their usual medications. Dobutamine stress testing (10 mcg/kg/min for 5 minutes, increasing by 10 mcg/kg/min every 3 minutes to a 40 mcg/kg/min maximum) is a reasonable substitute when exercise isn’t feasible, with similar overall hemodynamic findings to exercise testing.

Asymptomatic patients with significant MS (MVA under 1.5 cm²) and exercise-induced pulmonary hypertension (SPAP >60 mmHg) or an exercise-induced mean gradient rise >15 mmHg are considered by current multisocietal guidance to benefit from earlier mitral valve intervention, independent of resting severity alone.

Valve Morphology Scoring for Intervention Planning

Morphology scoring exists to answer a different question than the severity-grading methods above: not how severe is the stenosis, but how favorably will this specific valve respond to percutaneous balloon mitral commissurotomy (PMC).

The Wilkins Score

Four anatomic features are each graded 1 (most favorable) to 4 (least favorable), for a total score of 4–16:

Grade	Mobility	Leaflet Thickening	Calcification	Subvalvular Thickening
1	Highly mobile valve; only leaflet tips restricted	Leaflets near-normal thickness (4–5 mm)	A single area of increased echo brightness	Minimal thickening just below the leaflets
2	Mid and basal leaflet segments move normally	Mid-leaflet segments normal; considerable thickening of the edges (5–8 mm)	Scattered brightness confined to the leaflet margins	Thickening of chordae extending to one-third of chordal length
3	Valve continues to move forward in diastole, mainly from the base	Thickening extends through the entire leaflet (5–8 mm)	Brightness extends into the mid-portion of the leaflets	Thickening extends to the distal third of the chordae
4	No or minimal forward leaflet motion in diastole	Considerable thickening of all leaflet tissue (>8–10 mm)	Extensive brightness throughout most of the leaflet tissue	Extensive thickening and shortening of all chordae, down to the papillary muscles

What the total score means for PMC outcome (per the EACVI Echo Handbook’s interpretation of the original Wilkins data):

Total Wilkins score	Interpretation
≤ 8	Correlates with good results after PMC
> 8 but ≤ 12	Does not preclude PMC in selected cases
> 12	Associated with poor results after PMC

A score >8 is the threshold most commonly cited as predicting a less favorable PMC candidate, but as the table above shows, scores in the 9–12 range are not an automatic contraindication — they shift the decision toward careful selection rather than ruling PMC out. The reporting-guide literature also flags an important blind spot in the Wilkins system: it does not specifically weight the site of commissural calcification, which independently predicts procedural success — two valves with an identical total score can behave differently depending on whether calcification involves the commissures themselves.

The Cormier Score

A simpler three-group alternative that emphasizes calcification and the subvalvular apparatus over granular leaflet-by-leaflet grading:

Group	Mitral Valve Anatomy
1	Pliable, noncalcified anterior leaflet; mild subvalvular disease (chordae ≥10 mm long)
2	Pliable, noncalcified anterior leaflet; severe subvalvular disease (chordae under 10 mm long)
3	Calcification of the mitral valve of any extent (assessed by fluoroscopy), regardless of subvalvular status

Group 3 — calcification of any extent — is treated as an unfavorable characteristic across current guidance, independent of the Wilkins total. A valve that scores poorly on both systems, or that has an outright contraindication below, is generally referred for surgical repair or replacement instead of PMC — see Prosthetic Heart Valves for how a replaced valve is then followed echocardiographically.

Contraindications to PMC

Per the 2025 ESC/EACTS guideline:

• MVA >1.5 cm² (unless symptoms cannot be explained otherwise and anatomy is favorable)
• LA thrombus (with specific exceptions for appendage-only thrombus under anticoagulation — see the full guideline)
• More than mild MR
• Severe or bicommissural calcification
• Absence of commissural fusion (as in degenerative MAC-related MS — there is nothing to split)
• Severe concomitant aortic valve disease, or combined severe tricuspid stenosis and regurgitation requiring surgery
• Concomitant coronary disease requiring bypass surgery

Practical Pearls and Common Mistakes

• Always report the heart rate at which gradients were measured — it is essential for comparing serial studies and for interpreting whether a given gradient reflects true progression or just a faster heart rate on the day of the scan.
• Off-axis planimetry is probably the single most common technical error — confirm the plane with biplane/3D guidance rather than trusting a single 2D short-axis sweep, especially when the result will drive a management decision.
• Don’t trust pressure half-time in the presence of more-than-mild AR, in the first 24–72 hours after commissurotomy, or in mitral annular calcification — use planimetry (ideally 3D) as the primary method in these settings instead.
• Watch for the MAC “pseudo-severe” pattern: a large A-wave from diastolic dysfunction inflating the calculated gradient despite a non-severe orifice area. If the orifice and gradient disagree in an older patient with MAC, trust the orifice measurement (by 3D if feasible) over the gradient.
• Grade concomitant MR before committing to a PMC recommendation — more than mild MR is an outright contraindication, and even milder MR will inflate the measured transmitral gradient, since PISA-for-MS aside, most of this page’s other methods assume no significant coexisting regurgitation.
• Reconcile disagreement between methods systematically, not by picking whichever number looks more “severe” — when planimetry and PHT disagree, ask which assumption is most likely violated (poor acoustic window or oblique plane for planimetry; abnormal LA/LV compliance, more-than-mild AR, or a recent commissurotomy for PHT).
• A coexisting atrial septal defect with MS (Lutembacher syndrome) decompresses the LA, shortens PHT, and can mask true severity hemodynamically — worth considering specifically when the echocardiographic and clinical pictures don’t match.
• Assess the right heart and other valves every time: aortic stenosis severity can be underestimated when severe MS limits forward flow, and tricuspid involvement (rheumatic or functional) is common enough in MS that it changes surgical planning if more than mild.